CJC-1295 — Peptide Protocol Wiki reference
patient_educationexpert_opinion · status: needs_provider_reviewDetails
Summary (generated — provider review required)
CJC-1295 No DAC (Mod GRF 1-29): Research Guide | Peptide Protocol Wiki Skip to main content 🧬 Peptide Protocol Wiki Peptides Side Effects New Learn Directory Tools Blog News About ⌘K ⌘K 🌱 New to Peptides? Start the 7-step beginner guide Peptides Side Effects New Directory Learn Tools Blog News About CJC-1295 without DAC 📋 Overview 🧬 Molecule 🔄 Similar ⚠️ Side Effects 💉 Dosing 🔬 Research 🚨 Risks 👥 Community 📊 Community Data Home Peptides CJC-1295 without DAC Growth Hormone Anti-Aging & Longevity preclinical CJC-1295 without DAC Also known as: Modified GRF(1-29), Mod GRF 1-29, GRF(1-29) NH2 Compare with 1 peptide Research compiled by Peptide Protocol Wiki 📅 Updated February 8, 2026 Citations Verified TL;DR CJC-1295 without DAC (Modified GRF 1-29) is a synthetic 29-amino acid analog of growth hormone-releasing hormone with four amino acid substitutions for enhanced stability. Unlike its DAC-conjugated counterpart, it has a short half-life of approximately 30 minutes, producing discrete GH pulses that closely mimic natural physiology.
The original source document remains the source of truth. Generated summaries are not authoritative.
Linked assets (13) · phenotypes (0)
evidence_reference, safety_reference, dosing_reference, contraindication_reference, mechanism
Findings (54) · awaiting review (38)
mechanism · pending
The critical pharmacological difference lies in the duration of receptor engagement.
mechanism · pending
This somatostatin modulation preserves the pulsatile GH secretion pattern that is important for normal GH physiology.
safety · pending
CJC-1295 No DAC (Mod GRF 1-29): Research Guide | Peptide Protocol Wiki Skip to main content 🧬 Peptide Protocol Wiki Peptides Side Effects New Learn Directory Tools Blog News About ⌘K ⌘K 🌱 New to Peptides?
dosing · pending
Start the 7-step beginner guide Peptides Side Effects New Directory Learn Tools Blog News About CJC-1295 without DAC 📋 Overview 🧬 Molecule 🔄 Similar ⚠️ Side Effects 💉 Dosing 🔬 Research 🚨 Risks 👥 Community 📊 Community Data Home Peptides CJC-1295 without DAC Growth Hormone Anti-Aging & Longevity preclinical CJC-1295 without DAC Also known as: Modified GRF(1-29), Mod GRF 1-29, GRF(1-29) NH2 Compare with 1 peptide Research compiled by Peptide Protocol Wiki 📅 Updated February 8, 2026 Citations Verified TL;DR CJC-1295 without DAC (Modified GRF 1-29) is a synthetic 29-amino acid analog of growth hormone-releasing hormone with four amino acid substitutions for enhanced stability.
safety · pending
Browse all growth hormone peptides → Table of Contents 📌 TL;DR • Produces discrete, physiological GH pulses similar to natural GHRH signaling • Enhanced stability over native GHRH due to DPP-IV resistant modifications • Short half-life allows rapid clearance if adverse effects occur • Synergistic GH release when combined with ghrelin-mimeti
safety · pending
c peptides Community-Reported Side Effects Anecdotal ?
mechanism · pending
Binding to the GHRH-R activates the Gs-adenylate cyclase-cAMP-PKA signaling cascade, which promotes both the transcription of the growth hormone gene and the exocytotic release of stored GH-containing secretory granules.
mechanism · pending
The mechanism is identical to that of its DAC-conjugated counterpart and of native GHRH.
dosing · pending
📋 Protocol Quick-Reference Pulsatile growth hormone release, typically combined with a GHRP (ipamorelin) 💉 Dosing Amount 100 mcg per injection (1-2 mcg/kg saturation dose) Frequency 2-3 times daily Duration 8-12 weeks 💊 Administration Route SC Schedule 2-3 times daily Timing Before sleep (to amplify nocturnal GH surge), upon waking, and optionally mid-afternoon; must be on empty stomach (2-3 hours post-meal); avoid food for 30 min after injection ✓ Rotate injection sites 📅 Cycle Duration 8-12 weeks Repeatable Yes Preparation & Storage Diluent: Bacteriostatic water Storage: Store lyophilized peptide at -20C.
dosing · pending
⚗️ Suggested Bloodwork ( 6 tests) IGF-1 When: Baseline Why: Primary pharmacodynamic marker Fasting glucose and HbA1c When: Baseline Why: GH elevation can impair glucose tolerance Fasting insulin When: Baseline Why: Baseline insulin sensitivity Thyroid panel (TSH, Free T3, Free T4) When: Baseline Why: GH affects thyroid hormone conversion CMP When: Baseline Why: Liver and kidney function IGF-1 When: 4-6 weeks Why: Confirm GH axis stimulation 💡 Key Considerations → Almost always used in combination with ipamorelin (100-200 mcg) for synergistic GH release (3-5x amplification vs either alone) → Administe
contraindication · pending
r on an empty stomach - food and hyperglycemia blunt the GH response → Contraindication: Avoid in active cancer, diabetic retinopathy, or pituitary tumors; use caution in diabetes due to potential glucose effects Subscribe to unlock this content Get weekly peptide research summaries, new study alerts, and protocol updates — free.
outcome · pending
Restore access No thanks, continue reading Related Reading Peptide CJC-1295 DAC long-acting GHRH analog with Drug Affinity Complex Peptide Ipamorelin selective growth hormone secretagogue Peptide Sermorelin GHRH analog for growth hormone release How CJC-1295 without DAC works at the cellular level Overview of CJC-1295 without DAC benefits and applications Scientific Details Molecular Formula C152H252N44O42 Molecular Weight 3367.9 Da CAS Number 863288-34-0 Sequence YADAIFTQSYRKVLAQLSARKLLQDILSR What is CJC-1295 without DAC?
mechanism · pending
The peptide is based on the first 29 amino acids of human GHRH, which constitute the minimum fragment required for full biological activity at the GHRH receptor.
outcome · pending
Four strategic amino acid substitutions at positions 2, 8, 15, and 27 have been incorporated to improve metabolic stability, particularly resistance to cleavage by dipeptidyl peptidase IV (DPP-IV), the primary enzyme responsible for rapid inactivation of native GHRH.
mechanism · pending
The combination of GHRH analog and ghrelin-mimetic produces synergistic GH release that exceeds the effect of either compound alone, as they act through complementary receptor pathways.
mechanism · pending
Mechanism of Action # CJC-1295 without DAC functions as a selective agonist of the GHRH receptor (GHRH-R), a G protein-coupled receptor expressed on somatotroph cells in the anterior pituitary gland.
mechanism · pending
the peptide is cleared from the circulation within approximately 30 minutes, producing a brief burst of GHRH receptor activation followed by rapid return to baseline.
mechanism · pending
The GH-releasing effect of Modified GRF(1-29) is subject to physiological regulation by somatostatin, the hypothalamic inhibitor of GH release.
outcome · pending
The downstream effects of GH release stimulated by Modified GRF(1-29) include increased hepatic production of insulin -like growth factor 1 (IGF-1), stimulation of protein synthesis and muscle growth, promotion of lipolysis and fat oxidation, and enhancement of tissue repair processes.
outcome · pending
The amino acid modifications in Modified GRF(1-29) were characterized in a series of structure-activity relationship studies that demonstrated the four substitutions (D-Ala2, Gln8, Ala15, Leu27) improved metabolic stability while preserving full GHRH receptor agonist activity 1 .
regulatory · pending
Important Considerations # CJC-1295 without DAC is an investigational compound that has not been approved for clinical use by any regulatory agency.
regulatory · pending
Unlike sermorelin, which had previous FDA approval as a diagnostic and therapeutic agent, Modified GRF(1-29) has not undergone independent clinical development separate from the CJC-1295 DAC program.
dosing · pending
The short half-life of Modified GRF(1-29) necessitates multiple daily injections (typically 2 to 3 times daily) to maintain GH axis stimulation, which is a significant practical limitation compared to the weekly dosing of CJC-1295 DAC.
safety · pending
However, the short half-life is also a safety advantage, as any adverse effects resolve rapidly upon discontinuation.
dosing · pending
Key Research Findings # Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults , published in Journal of Clinical Endocrinology and Metabolism (Teichman SL et al., 2006; PMID: 16352683): Clinical study characterizing the pharmacology of the CJC-1295 peptide sequence (used in both DAC and non-DAC forms); demonstrated dose-dependent GH and IGF-1 stimulation in healthy adults.
dosing · pending
Great Northern Peptides 8 /10 International From $ 65.00 Biotech Peptides 7.7 /10 US Domestic Particle Peptides 7.7 /10 International Verified Peptides 7.6 /10 US Domestic From $ 40.00 Ascension Peptides 7.5 /10 US Domestic Cernum Biosciences 7.5 /10 US Domestic View all 40 vendors → Explore Further Calculate CJC-1295 without DAC doses Pre-filled reconstitution and dose math for CJC-1295 without DAC New to peptides?
dosing · pending
Covers lipolytic mechanism without IGF-1 effects, weight management data, dosing, and GRAS safety status.
dosing · pending
Characterized the modified GRF(1-29) sequence that forms the basis of both CJC-1295 DAC and non-DAC forms Demonstrated full GHRH receptor agonist activity of the four amino acid modifications Confirmed dose-dependent GH-releasing activity in humans Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse , published in American Journal of Physiology - Endocrinology and Metabolism (Alba M et al., 2006; PMID: 16822960): Preclinical study demonstrating that once-daily CJC-1295 normalizes growth in GHRH knockout mice, confirming the biological activity of the modified GRF(1-29) peptide sequence in vivo.
dosing · pending
CJC-1295 normalized body weight and length in GHRH knockout mice with daily administration Confirmed that the CJC-1295 peptide sequence maintains full GHRH receptor agonist activity in vivo Demonstrated dose-dependent growth normalization in a GHRH-deficient model Referen
dosing · pending
ces # Related Reading # CJC-1295 without DAC research studies and evidence CJC-1295 without DAC dosing protocols CJC-1295 without DAC side effects profile AOD-9604 research guide GHRP-2 research guide Footnotes # Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA.
dosing · pending
↩ Stay current on CJC-1295 without DAC research We summarize new studies, safety updates, and dosing insights — delivered biweekly.
outcome · pending
What are the benefits of CJC-1295 without DAC?
outcome · pending
Research suggests the following potential benefits of CJC-1295 without DAC: Produces discrete, physiological GH pulses similar to natural GHRH signaling.
safety · pending
Short half-life allows rapid clearance if adverse effects occur.
safety · pending
What are the side effects of CJC-1295 without DAC?
safety · pending
Reported side effects of CJC-1295 without DAC include injection site reactions.
safety · pending
Most reported side effects are mild and transient.
safety · pending
Comprehensive human safety data may be limited.
safety · pending
Consult the detailed side effects profile for full information.
regulatory · pending
Is CJC-1295 without DAC FDA approved?
Processing
Processed into 14 searchable sections.